Chronic treatment of β-blocker inhibited mucus hypersecretion and MUC5AC expression exposed to cigarette smoking through β-arrestin2–ERK1/2 pathway

Bei He,Yujiao Zhou,Yang Guo,Ming Xu,Youyi Zhang
IF: 24.3
2014-01-01
European Respiratory Journal
Abstract:BACKGROUND Progression of COPD is associated with the small airway obstruction by accumulation of inflammatory mucous exudates, while MUC5AC is the predominant component of mucous exudates. AIMS To explore the effects of chronic propranolol administration on airway mucins hypersecretion and the potential mechanisms of the protection of β-blocker against airway MUC5AC hyperproduction. METHODS Rat model exposed to cigarette smoke and NCI-H292 cell line were used to study the effects of propranolol on mucus production, MUC5AC expression and contribution of β 2- AR signaling. The isolated tracheal segments were studied in vitro to assess the contractile function of the smooth muscle. RESULTS 1. In cigarette smoke-exposed rats9 model, chronic administration of propranolol (25mg kg -1 d -1 ) significantly attenuated the airway goblet cell metaplasia, mucus hypersecretion and MUC5AC expression. 2. Pretreatment NCI-H292 cells with propranolol (10 -5 M), ICI118551(10 -5 M) or β 2 AR–targeted siRNA (100 nM) reduced MUC5AC mRNA and protein levels by cigarette smoke extract stimulation. The mechanism might be β 2 -AR mediated MUC5AC expression induced by smoking through β-arrestin2–ERK1/2 pathway. 3. Chronic administration of propranolol increased the relaxant effect mediated by the β 2 -AR and decreased the contractile response to acetylcholine. CONCLUSION β 2 -AR-β-arrestin2–ERK1/2 signaling is required for cigarette smoke-induced MUC5AC expression. Chronic treatment of β-blocker improved airway mucus hypersecretion resulting from smokingwithout increased the contractile response. Those data may contribute to the optimization of β 2 -AR target therapy in COPD.
What problem does this paper attempt to address?